奥妥珠单抗β治疗AQP4阳性视神经脊髓炎谱系疾病:3期随机对照试验
这项多中心、随机、双盲3期试验评估了新型糖工程化II型抗CD20单抗奥妥珠单抗β(MIL62)在AQP4-IgG阳性视神经脊髓炎谱系疾病(NMOSD)患者中的疗效与安全性。受试者按1:1随机接受奥妥珠单抗β 1000 mg(n=45)或安慰剂(n=46)静脉给药。主要终点(52周内首次裁定复发时间)达成:奥妥珠单抗β组复发2/45(4.4%),安慰剂组21/46(45.7%)(HR=0.069,95%CI 0.016-0.296,P<0.0001)。
要点
- 奥妥珠单抗β显著降低AQP4-IgG+ NMOSD患者52周内复发风险(HR=0.069)。
- 奥妥珠单抗β组复发率4.4%,安慰剂组45.7%。
- 两组≥3级治疗相关不良事件发生率相似(6.7% vs 6.5%)。
核心结论
- 奥妥珠单抗β可显著降低AQP4-IgG阳性NMOSD患者的复发风险,且安全性可接受。
研究设计与样本
- 多中心、随机、双盲3期试验,纳入18-70岁AQP4-IgG血清阳性且EDSS≤7.0的NMOSD患者。
- 受试者按1:1随机接受静脉奥妥珠单抗β 1000 mg(n=45)或安慰剂(n=46)。
- 主要终点为52周内首次裁定复发时间。
主要发现
- 奥妥珠单抗β组复发2/45(4.4%),安慰剂组21/46(45.7%)。
- 风险比HR=0.069(95%CI 0.016-0.296),P<0.0001。
- ≥3级治疗相关不良事件发生率:奥妥珠单抗β组6.7%,安慰剂组6.5%。
关键数值与推荐
- 主要终点达成:52周内首次裁定复发时间显著延长(HR=0.069,95%CI 0.016-0.296,P<0.0001)。
- ≥3级治疗相关不良事件发生率组间相似(6.7% vs 6.5%)。
临床怎么用
- 奥妥珠单抗β可作为AQP4-IgG阳性NMOSD患者的一种糖工程化II型抗CD20治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although CD20-directed B cell depletion has long been used in neuromyelitis optica spectrum disorder (NMOSD), high-quality, large-scale, randomized controlled trials remain limited. In this multicenter, randomized, double-blind phase 3 trial, we evaluated obinutuzumab β (MIL62), a novel glycoengineered type II anti-CD20 monoclonal antibody, in patients with NMOSD. Eligible participants aged 18-70 years with aquaporin-4-immunoglobulin G (AQP4-IgG)-seropositive NMOSD and an Expanded Disability Status Scale (EDSS) score of 7.0 or lower were randomly assigned (1:1) to receive intravenous obinutuzumab β 1,000 mg (n = 45) or placebo (n = 46). The primary outcome-time to first adjudicated relapse on or before week 52-was met: relapse occurred in two of 45 (4.4%) obinutuzumab β-treated participants and in 21 of 46 (45.7%) placebo-treated participants (hazard ratio = 0.069, 95% confidence interval: 0.016-0.296, P < 0.0001). The incidence of grade 3 or higher treatment-related adverse events was similar between the obinutuzumab β group (6.7%) and the placebo group (6.5%). These findings support obinutuzumab β as a glycoengineered type II anti-CD20 therapeutic option for patients with AQP4-IgG+ NMOSD. ClinicalTrials.gov identifier: NCT05314010 .
引用
- Wu L, Gu L, Fan W, et al. Obinutuzumab β for aquaporin-4-positive neuromyelitis optica spectrum disorder: a phase 3 randomized controlled trial. Nat Med. 2026. PMID: 42575985. doi:10.1038/s41591-026-04583-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。